Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients

• Status: Completed
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled analgesia (PCA) for mucositis pain in pediatric cancer patients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer Hospital Egypt 57357
• Treatments: Morphine; Nalbuphine

Criteria

Inclusion Criteria:

• Newly diagnosed Primary AML or HSCT and ALL with oral mucositis grade III OR IV presenting in the study period.

• Age above 5 year and below 18 years

• Written Informed Consent from parents/guardian

Exclusion Criteria:

• History of mental retardation

• known or suspected allergy to any narcotics

• Presence of any other co-morbidity:

• kidney (Crcl <50)

• liver (liver enzymes more than 10 folds)

• chest (SPO2 <92% on room air)

• cardiac disease (ejection fraction <40%)

• terminal patients who scheduled for palliative care